Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Diagnostic Value Of Fibulin-3 For Malignant Pleural Mesothelioma: A Systematic Review And Meta-analysis
Ran Ren, P. Yin, Y. Zhang, J. Zhou, Yixing Zhou, R. Xu, Hai Lin, C. Huang
Published 2016 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Background Several studies have investigated the diagnostic value of fibulin-3 for malignant pleural mesothelioma (MPM), but the results were various. Therefore, we performed a systematic review and meta-analysis to evaluate the diagnostic value of fibulin-3 for MPM. Results Eight studies were included in this work. The overall sensitivity of blood fibulin-3 were 0.87 (95% CI, 0.58 – 0.97) and 0.89 (95% CI, 0.77 – 0.95), respectively. The overall sensitivity and specificity of PF fibulin-3 for MPM were 0.73 (95% CI, 0.54 – 0.86) and 0.80 (95% CI, 0.60 – 0.91), respectively. The area under curve of blood and pleural effusion (PF) Fibulin-3 were 0.94 (95% CI, 0.91 – 0.96) 0.83 (95% CI, 0.79 – 0.86), respectively. Methods PubMed and EMBASE databases were searched up to July 29, 2016 to verify studies investigating the diagnostic value of fibulin-3 for MPM. The quality of eligible studies was assessed using the revised Quality Assessment for Studies of Diagnostic Accuracy tool (QUADAS-2). The overall sensitivity and specificity were pooled using a bivariate model. Conclusion Fibuoin-3 is a useful diagnostic marker for MPM.
This paper references
QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies
P. Whiting (2011)
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
The established and future biomarkers of malignant pleural mesothelioma.
V. Panou (2015)
Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data.
S. Walter (2002)
Role of fibulin-3 in the diagnosis of malignant mesothelioma
M. Agha (2014)
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
Systematic reviews and meta-analyses of diagnostic test accuracy.
M. Leeflang (2014)
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
H. Kaya (2015)
Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.
H. Lin (2014)
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
Incidence and survival trends for Oncotarget 84858 www.impactjournals.com/oncotarget malignant pleural and peritoneal mesothelioma
Mj Soeberg (1982)
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
M. Kirschner (2015)
The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed.
J. Deeks (2005)
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Weiquan Zhang (2015)
Perspective on malignant pleural mesothelioma diagnosis and treatment.
Ori Wald (2016)
Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma
A. McCullough (2013)
Incidence and survival trends for Oncotarget 84858 www.impactjournals.com/oncotarget malignant pleural and peritoneal mesothelioma, Australia, 1982-2009
MJ Soeberg (2016)
Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions
A. Elgazzar (2014)
Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.
Z. Hu (2014)
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
Case-control and two-gate designs in diagnostic accuracy studies.
A. Rutjes (2005)
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews.
J. Reitsma (2005)
Incidence and survival trends for malignant pleural and peritoneal mesothelioma
M J Soeberg (1982)
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma
J. Creaney (2015)
Malignant pleural mesothelioma: a comprehensive review.
R. Ismail-Khan (2006)
Diagnostic Accuracy of Natriuretic Peptides for Heart Failure in Patients with Pleural Effusion: A Systematic Review and Updated Meta-Analysis
Zhi-jun Han (2015)
Preferred reporting items for systematic reviews and Oncotarget 84859 www.impactjournals.com/oncotarget meta-analyses: the PRISMA statement
D Moher (2009)
Preferred reporting items for systematic reviews and www.impactjournals.com/oncotarget meta-analyses: the PRISMA statement
D Moher (2009)
This paper is referenced by
Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on
C. Ledda (2018)
Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?
Zehra Bozdağ (2019)
The diagnostic potential and biological significance of MicroRNA in Malignant Pleural Mesothelioma
Kimberly A. Birnie (2016)
Asbestos-Related Diseases and Blood Biomarkers
A. Franko (2019)
Analysis of fibulin‐3 after exposure to asbestos‐like fibers
V. Rapisarda (2017)
Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma
Kimberly A. Birnie (2017)
Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini‐review
Yan-qiu Han (2020)
Extracellular Interactions between Fibulins and Transforming Growth Factor (TGF)-β in Physiological and Pathological Conditions
T. Tsuda (2018)
A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma
Bill T V Duong (2020)
Biomarkers in the diagnosis of pleural diseases: a 2018 update
J. M. Porcel (2018)
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
Correction to: Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?
Zehra Bozdağ (2020)
MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
Kimberly A. Birnie (2019)
Validation of Calprotectin As a Novel Biomarker For The Diagnosis of Pleural Effusion: a Multicentre Trial
M. Botana-Rial (2020)
Diagnostic value of D2-40 immunostaining for malignant mesothelioma: a meta-analysis.
C. He (2017)
Lung Cancer Biomarkers in Proximal Fluids
Gabriel D. Dakubo (2019)
Biomarkers in mesothelioma
D. Arnold (2018)
Circulating and local nuclear expression of survivin and fibulin-3 genes in discriminating benign from malignant respiratory diseases: correlation analysis
M. Hassan (2020)